New hope for scarred lungs: experimental drug enters Mid-Stage testing
Disease control
Recruiting now
This study is testing whether a new drug called MTX-463 can help slow the progression of idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. About 164 adults with IPF will receive either the drug or a placebo via IV infusion every four weeks for six months. The …
Phase: PHASE2 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC